By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine is pulling its initial public offering citing adverse market conditions.

In a document filed with the US Securities and Exchange Commission on Tuesday, the Austin, Texas-based multiplex molecular diagnostics firm said it plans to withdraw its IPO due to market conditions, but it did not elaborate further. A company spokesman also declined to comment further on the withdrawal of the IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.